Akeso Biopharma (HKG: 9926), a leading biopharmaceutical company based in China, has announced the submission of a new indication supplementary approval filing for its bispecific antibody (BsAb) drug candidate, cadonilimab (AK104). The company is seeking to expand the use of cadonilimab in combination with chemotherapy as a first-line treatment for patients with unresectable, locally advanced, recurrent, or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. The National Medical Products Administration (NMPA) is currently reviewing the application.
Cadonilimab, which targets both programmed death-1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4-targeted (CTLA-4), was conditionally approved in China in June 2022 for the treatment of patients with recurrent or metastatic cervical cancer who had previously failed platinum-based chemotherapy.- Flcube.com
